DIENSTAG, 28. APRIL 2026

The Daily

Arbeitsschutz-Tag. Kaffee mit Helm.

Wien heute: ☁️ teilweise bewölkt, aktuell 6°C (gefühlt 6°C). Wind 4 km/h, Luftfeuchtigkeit 75%. Sonnenaufgang 05:41, Sonnenuntergang 20:04.

NBA

Three-Game Queue, No Box-Score Traps

Detroit–Orlando Game 4, Oklahoma City–Phoenix Game 4 and Minnesota–Denver Game 5 all sat on Monday’s playoff slate. This is the spoiler-safe zone: no scores, winners, stat lines or postgame series state here. Wikihoops did not yet show a mature consensus for the full slate, so start with the matchup you care about most and check the game page before pressing play.
Source: NBA.com schedule + Wikihoops

Embiid’s Return Did Not Solve Boston’s Math

John Schuhmann separates the emotion of Joel Embiid’s return from the tactical reality of the matchup. Embiid produced, but Boston’s spacing, pick-and-roll targeting and 3-point volume kept the underlying problem in Philadelphia’s lap.
Source: NBA.com

Foul-Up-Three Enters the Aesthetics Fight

Zach Kram uses a Spurs–Blazers ending to explain why intentional fouls when leading by three are spreading. The trend line is clean: 11.5 percent of chances in a 2010 Synergy study versus 34.2 percent over the last two seasons in the final 10 seconds.
Source: ESPN

Denver–Minnesota Turned Into an Availability Story

The useful angle is strictly pre-tip: Aaron Gordon was ruled out with left calf tightness after warmups, while Minnesota had its own major absences. That made Game 5 a tactical availability puzzle before the ball went up, without needing any outcome language.
Source: Yahoo Sports

Biotech & Pharma

Fenebrutinib Becomes Roche’s BTK Test Case

Roche plans regulatory filings for fenebrutinib after two Phase 3 multiple-sclerosis trials cut annualized relapse rates versus teriflunomide by 51.1 and 58.5 percent over 96 weeks. The harder question is safety, because Roche also disclosed an imbalance in deaths across the programme. For the BTK class, this is no longer just an MS readout; it is a regulatory test of whether the mechanism still has a path after liver-toxicity and broader safety concerns.
Source: Reuters / Roche

Merck Buys Time Before Keytruda’s Cliff

Merck’s $5.7bn deal for Terns Pharmaceuticals is a pipeline hedge before Keytruda loses exclusivity. The main asset is TERN-701, an early CML candidate expected to move into late-stage testing in late 2026 or early 2027.
Source: FT

Gilead Pays for the Next CAR-T Step

Gilead is buying Arcellx for up to $7.8bn to deepen its multiple-myeloma cell-therapy bet. The centrepiece is anito-cel, a next-generation CAR-T candidate with an FDA decision for relapsed patients expected by December.
Source: FT

Ouro Pushes T-Cell Engagers Beyond Cancer

Gilead’s nearly $2.2bn Ouro Medicines deal moves T-cell-engager logic from oncology into autoimmune disease. Ouro’s early antibody programme is being treated as a “pipeline-in-a-product” bet rather than a single-asset tuck-in.
Source: FT

Science / Immuno-Oncology

CAR-PRISM Tests CAR-T Before Myeloma Breaks Out

CAR-PRISM tests ciltacabtagene autoleucel in high-risk smoldering multiple myeloma, pushing CAR-T into a precursor state rather than late relapse. All 20 treated patients became MRD-negative within two months and remained MRD-negative at a median 15.3 months of follow-up. The clinical question is now less raw activity than whether early interception can justify CAR-T-level risk and logistics.
Source: Nature Medicine

The FDA Finds 2,200 Trial-Reporting Gaps

The FDA has sent more than 2,200 letters to sponsors and researchers over apparently missing ClinicalTrials.gov results. For oncology, the issue is practical: unpublished negative or incomplete data distort treatment choices and the design of follow-on trials.
Source: NYT

Cancer Mortality Falls, Colorectal Signals Persist

SPIEGEL’s Destatis readout separates two trends: age-standardized cancer mortality is falling, while absolute deaths still rise with demographics. The outlier remains colorectal cancer in younger groups, where hospital treatments are increasing across several under-50 cohorts.
Source: SPIEGEL+

Local 4-1BB Signalling Opens MSS Colorectal Cancer

A Phase 1b study combines cibisatamab with FAP-4-1BBL in heavily pretreated MSS metastatic colorectal cancer. In 52 patients, safety was manageable, confirmed partial responses reached 13.5 percent, and the translational signal showed systemic and intratumoral T-cell activation.
Source: Nature Medicine

Wien für Kinder

FALTER sortiert die Kinderwoche neu

Mozart für Kinder - 28.4., 10 Uhr, Bezirksmuseum Josefstadt, 1080 Wien, Schmidgasse 18
Mirabilia - ab 29.4., Dschungel Wien, 1070 Wien, Museumsplatz 1
Krabbelnest Wickenburg - freie Plätze ab sofort und ab September 2026
Festival der Theaterwerkstätten - 9. bis 13.5., Dschungel Wien

Der FALTER-Newsletter ist nach dem dichten Wochenende vor allem als Wochenkarte nützlich: Was ist vorbei, was läuft jetzt noch, und was kann man sauber vorausplanen. Für heute bleiben Mozart am Vormittag und die nächsten Dschungel-Termine die belastbaren Haken.
Source: FALTER

Mozart Passt Noch in den Dienstagvormittag

Das Babykonzert im Bezirksmuseum Josefstadt ist genau der kleine Alltagstermin, den man morgens noch entscheiden kann. Klassik läuft hier so niedrigschwellig, dass Babys liegen, krabbeln oder schlafen dürfen.
Source: FALTER

Mirabilia Startet Morgen im MQ

„Mirabilia“ bringt Tanz, Objekte und Barockmusik für Kinder ab zwei Jahren in den Dschungel Wien. Die Termine laufen ab Mittwoch bis 2. Mai; die direkte Dschungel-Seite steht hier, falls Tickets schneller gehen sollen.
Source: FALTER

Zähneputzen Wird Zur einfachen Abendregel

Die KIWI-Expertin Barbara Barth setzt den wichtigsten Punkt sehr klar: Abends nach dem Essen putzen. Nach Saurem oder Süßem hilft zuerst Wasser im Mund, wichtiger als starre Wartezeiten ist aber die verlässliche Routine.
Source: FALTER